<DOC>
	<DOC>NCT01054443</DOC>
	<brief_summary>This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of S-888711 in the treatment of subjects with immune thrombocytopenia. Eligible subjects will be randomized into one of four treatment groups to receive S-888711 0.5 mg, 0.75 mg, or 1.0 mg or placebo.</brief_summary>
	<brief_title>A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>A signed and dated written informed consent Males and females ≥ 18 years of age All subjects must agree to use barrier contraception Diagnosis of ITP Subjects &gt; 60 years must have had a diagnostic bone marrow aspiration Relapsed persistent or chronic ITP status, with or without prior splenectomy (exception: in Hungary only splenectomized subjects will be enrolled), after having failed at least 1 prior ITP therapy (excluding TPO agonists) and have a platelet count &lt; 30,000/μL if not taking medications or &lt; 50,000/μL despite concomitant steroids or other ITP therapies, such as danazol or immunosuppressive drugs Subjects receiving steroid therapy must be on a stable dose PT and APTT within 20% of the upper limit of normal Subjects receiving stable dosages of cyclosporine A, mycophenolate mofetil, azathioprine, or danazol are allowed. The dosages of all these medications must be stable for at least 4 weeks prior to Visit 1 (Day 1) History of clinically important hemorrhagic clotting disorder Females who are pregnant, lactating, or taking oral contraceptives History of alcohol/drug abuse or dependence within 1 year Use of the following drugs or treatment prior to Visit 1 (Day 1): Within 12 weeks alemtuzumab, multidrug systemic chemotherapy, stem cell therapy; Within 8 weeks rituximab Within 2 weeks platelet transfusions or plasmapheresis treatment Within 4 weeks use of antiplatelet or anticoagulant drugs Within 1 week Rho(D) immune globulin or intravenous immunoglobulin History of clinically significant cardiovascular or thromboembolic disease within 26 weeks prior to Screening Splenectomy within 4 weeks prior to Screening Clinically significant laboratory abnormalities Hemoglobin &lt; 10.0 g/dL for men or women, not clearly related to ITP Absolute neutrophil count &lt; 1000/mm3 Abnormal peripheral blood smear Total bilirubin &gt; 1.5 x upper limit of normal Alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal Aspartate aminotransferase (AST) &gt; 1.5 x upper limit of normal Creatinine &gt; 1.5 x upper limit of normal Human immunodeficiency virus (HIV) positive Hepatitis A IgM antibody (IgM HAV) positive, hepatitis B surface antigen (HbsAg) or hepatitis C antibody (HCV) positive Thyroid stimulating hormone (TSH) &gt; 1.5 x upper limit of normal Free thyroxine (T4) &gt; 1.5 x upper limit of normal Exposure to previous TPO mimetics/agonists (e.g., eltrombopag,romiplostim, E5501 [AKR501] or LGD4665) within 4 weeks prior to Screening Subjects unresponsive to previous TPO mimetics/agonists (e.g., eltrombopag, romiplostim, E5501 [AKR501] or LGD4665) Exposure to an investigative medication within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Immune Thrombocytopenia (ITP)</keyword>
	<keyword>Low Platelet Count</keyword>
	<keyword>Thrombocytopaenia</keyword>
	<keyword>S-888711</keyword>
	<keyword>Splenectomy</keyword>
	<keyword>Thrombopoiesis</keyword>
	<keyword>Hematologic Disease</keyword>
	<keyword>Auto-immune thrombocytopenic Purpura</keyword>
	<keyword>Relapsed Persistent or Chronic ITP</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Thrombotic Thrombocytopenic Purpura (TTP)</keyword>
</DOC>